Prometheus, Tarrot to Seek Crohn's Disease Biomarkers for PGx Applications | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories and Tarrot Laboratories today announced an exclusive research collaboration and license agreement to identify biomarkers associated with clinical response to anti-TNF therapies in Crohn's disease.

The deal covers genetic and serologic biomarkers as predictors of response to drugs such as Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab). Diagnostic tests would be developed from the biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.